Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Gleason Score & ISUP Grade

The Gleason scoring system is the most common grading system for prostate cancer.

Evidence-based context for fast calculator use

Purpose:
Gleason Score calculator converts primary and secondary biopsy patterns into ISUP Grade Groups to stratify prostate cancer aggressiveness.
Population:
patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment
Factors:
Primary Pattern, Secondary Pattern
Reference:
Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2016;40(2):244-252.
HomeGleason Score & ISUP Grade
Pin your most used calculators here by clicking the star in the dropdown.

Gleason Score & ISUP Grade

Clinical Context & Background

The Gleason scoring system is the most common grading system for prostate cancer. The ISUP (International Society of Urological Pathology) Grade Group system simplifies this into 5 groups to better accurately reflect prognosis, with Group 1 being the least aggressive and Group 5 being the most aggressive.
Primary Source EvidenceEpstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2016;40(2):244-252.
Formula Logic
Primary Pattern + Secondary Pattern = Total Score -> ISUP Group

Reference Data

ISUP GroupGleason ScoreDescription
Group 1≤ 6Clinically Indolent
Group 23 + 4 = 7Intermediate Favorable
Group 34 + 3 = 7Intermediate Unfavorable
Group 48High Risk
Group 59 - 10Highest Risk

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Gleason Score & ISUP Grade when gleason Score calculator converts primary and secondary biopsy patterns into ISUP Grade Groups to stratify prostate cancer aggressiveness.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Group 1 through Group 5.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm biopsy versus prostatectomy setting, PSA timing, grade group, clinical/pathologic stage, imaging, life expectancy, and treatment history.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Diagnostic, post-prostatectomy, genomic, and recurrence tools must be used only at their intended decision point.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment

How to apply this result

For a representative case, verify Primary Pattern, Secondary Pattern, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Prostate Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

D'Amico Risk ClassificationEpstein Criteria (Insignificant Cancer)PI-RADS™ v2.1 (Prostate MRI)

Frequently Asked Questions

When should Gleason Score & ISUP Grade be used?

Use it for patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment when all required inputs and the intended clinical setting are confirmed.

Can Gleason Score & ISUP Grade determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.